171 related articles for article (PubMed ID: 8436210)
21. In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells.
Muus P; Drenthe-Schonk A; Haanen C; Wessels H; Linssen P
Leuk Res; 1987; 11(4):319-25. PubMed ID: 3470578
[TBL] [Abstract][Full Text] [Related]
22. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
Yamauchi T; Kawai Y; Kishi S; Goto N; Urasaki Y; Imamura S; Fukushima T; Yoshida A; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 May; 92(5):546-53. PubMed ID: 11376564
[TBL] [Abstract][Full Text] [Related]
23. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
24. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Gandhi V; Xu YZ; Estey E
Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
[TBL] [Abstract][Full Text] [Related]
25. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
26. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Gandhi V; Robertson LE; Keating MJ; Plunkett W
Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
[TBL] [Abstract][Full Text] [Related]
27. Efficient formation of cytosine arabinoside-5'-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia.
Tanaka M; Yoshida S
Leuk Res; 1989; 13(10):931-6. PubMed ID: 2586146
[TBL] [Abstract][Full Text] [Related]
28. 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview.
Rustum YM; Raymakers RA
Pharmacol Ther; 1992 Dec; 56(3):307-21. PubMed ID: 1301593
[TBL] [Abstract][Full Text] [Related]
29. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
[TBL] [Abstract][Full Text] [Related]
30. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
31. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity.
Gruber A; Liliemark E; Tidefelt U; Paul C; Björkholm M; Peterson C; Liliemark J
Leuk Res; 1995 Oct; 19(10):757-61. PubMed ID: 7500654
[TBL] [Abstract][Full Text] [Related]
33. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
34. Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.
Momparler RL; Onetto-Pothier N; Bouffard DY; Momparler LF
Cancer Chemother Pharmacol; 1990; 27(2):141-6. PubMed ID: 2249330
[TBL] [Abstract][Full Text] [Related]
35. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
[TBL] [Abstract][Full Text] [Related]
36. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Estey EH; Keating MJ; McCredie KB; Freireich EJ; Plunkett W
Leukemia; 1990 Feb; 4(2):95-9. PubMed ID: 2304361
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
38. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
Tanaka M; Yoshida S
Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
40. In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.
Liliemark EK; Liliemark J; Pettersson B; Gruber A; Björkholm M; Peterson C
Leuk Lymphoma; 1993 Jul; 10(4-5):323-8. PubMed ID: 8220130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]